Clinical Trials Logo

Melanoma - Currently Enrolling clinical trials

View clinical trials related to Melanoma - Currently Enrolling.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02122861 Completed - Clinical trials for Non-small Cell Lung Cancer - Enrollment Completed

Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1

Start date: May 30, 2014
Phase: Phase 1
Study type: Interventional

This is a Phase 1 multi-center study to evaluate the clinical safety and immune response of ID-LV305 when injected intradermally in patients with advanced cancer. ID-LV305 is a novel immunotherapy agent designed to target dendritic cells and stimulate the body's immune system to fight the spread and growth of cancer for patients whose tumors express the NY-ESO-1 protein. Patients with melanoma, sarcoma, ovarian cancer, or small cell lung cancer that express NY-ESO-1 may be considered for the trial. Selected sites will be evaluating ID-LV305 with pembrolizumab for patients with melanoma who have inadequately responded to anti-PD-1 therapy.